Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy
This trial is conducted in Asia. The aim of this trial is to evaluate the haemostatic efficacy of activated recombinant human factor VII in cirrhotic patients scheduled to undergo partial hepatectomy due to liver cancer or benign tumours.
Acquired Bleeding Disorder|Cirrhosis
DRUG: activated recombinant human factor VII|DRUG: activated recombinant human factor VII|DRUG: placebo
The RBC transfusion requirements
Number of transfusion product units|Change in coagulation-related parameters|Adverse events
This trial is conducted in Asia. The aim of this trial is to evaluate the haemostatic efficacy of activated recombinant human factor VII in cirrhotic patients scheduled to undergo partial hepatectomy due to liver cancer or benign tumours.